Charles Schwab
VIRX

Charles Schwab’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Charles Schwab’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,430
Closed -$12.9K – 3573
2023
Q3 		$12.9K Hold
12,430
– – ﹤0.01% 3546
2023
Q2 		$17.5K Hold
12,430
– – ﹤0.01% 3574
2023
Q1 		$19.8K Hold
12,430
– – ﹤0.01% 3510
2022
Q4 		$18.1K Hold
12,430
– – ﹤0.01% 3511
2022
Q3 		$54K Buy
+12,430
New +$52.6K ﹤0.01% 3317
2022
Q2 		– Sell
-79,118
Closed -$377K – 3668
2022
Q1 		$377K Sell
79,118
-6,942
-8% -$20.9K ﹤0.01% 3160
2021
Q4 		$315K Hold
86,060
– – ﹤0.01% 3276
2021
Q3 		$691K Buy
86,060
+2,268
+3% +$22.4K ﹤0.01% 3028
2021
Q2 		$951K Buy
+83,792
New +$841K ﹤0.01% 2949
2015
Q3 		– Sell
-219
Closed -$139K – 3100
2015
Q2 		$139K Sell
219
-328
-60% -$174K ﹤0.01% 3027
2015
Q1 		$282K Buy
547
+201
+58% +$101K ﹤0.01% 2859
2014
Q4 		$186K Sell
346
-188
-35% -$84.7K ﹤0.01% 2992
2014
Q3 		$801K Buy
534
+11
+2% +$15.9K ﹤0.01% 2404
2014
Q2 		$716K Buy
523
+88
+20% +$102K ﹤0.01% 2490
2014
Q1 		$605K Buy
435
+87
+25% +$101K ﹤0.01% 2516
2013
Q4 		$347K Buy
348
+95
+38% +$98.2K ﹤0.01% 2730
2013
Q3 		$267K Sell
253
-24
-9% -$25.6K ﹤0.01% 2804
2013
Q2 		$321K Buy
+277
New +$309K ﹤0.01% 2705

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's VIRX Position: Q4 2023 in Review

Charles Schwab sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2023, closing a stake of 12,430 shares — an estimated $12.9K sold.

Charles Schwab first reported a position in VIRX in Q2 2013 and held it in 18 quarters. The position peaked at $951K in Q2 2021. 42 funds tracked by Wall St. Rank hold VIRX as of Q4 2023.

  • Charles Schwab reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Charles Schwab sold 12,430 Viracta Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $12.9K.
  • Charles Schwab first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Charles Schwab's Viracta Therapeutics, Inc. Common Stock position peaked at $951K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.